NanoBio Obtains $11,000,000 Series C Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a3c9d269-9940-4f70-b860-092334c9c7ce&Preview=1 -
Date
11/29/2012 -
Company Name
NanoBio -
Mailing Address
2311 Green Road Ann Arbor, MI 48105 -
Company Description
NanoBio Corporation is a biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat technology platform. -
Website
http://www.nanobio.com -
Transaction Type
Venture Equity -
Transaction Amount
$11,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Proceeds from the financing will be used to advance the company’s development programs for herpes labialis (cold sores), cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus (RSV) and genital herpes (HSV2). -
M&A Terms
-
Venture Investor
Venture Investors -
Venture Investor
Merck Capital Ventures -
Venture Investor
Perseus
